Parathyroid hormone (PTH) is well known for its anabolic actions in bone and is an effective therapeutic agent for the treatment of osteoporosis and localized osseous defects. Despite its clinical efficacy, its mechanisms of action are complex and elusive in particular in regard to its potential for regenerative approaches and wound healing. A key aspect of the complexity is that PTH anabolic actions are not the simple activation of osteoblasts, but require accessory cells in an intricate temporal and spatial organization. Data from the previous project award strongly support the ability of PTH to act on bone in an indirect manner through myeloid cells in the bone marrow microenvironment. The overall hypothesis of this project is that PTH acts via macrophage engulfment of apoptotic osteoblasts to produce coupling factors that recruit mesenchymal stem cells to form new bone. The specific phagocytosis of apoptotic cells is termed efferocytosis and is emerging as an integral process in tissue homeostasis, inflammation, autoimmunity and cancer, yet virtually nothing has been investigated regarding its role in the bone microenvironment. On a daily basis there are billions of cells undergoing apoptosis in the human body. Exposure of adjacent cells to the contents of dead and dying cells results in harmful inflammatory responses, yet when macrophages engulf apoptotic cells they release anti-inflammatory factors such as TGF? that are instrumental in recruiting mesenchymal stem cells. Macrophages utilize distinct receptor signaling pathways to identify apoptotic cells for efferocytosis. Such identification and signaling events represent intriguing and focused new pharmacologic targets to benefit bone regenerative strategies.
Three specific aims will dissect the ability of apoptotic osteoblasts to recruit phagocytic myeloid cells, the dependence of PTH anabolic actions on macrophage phagocytosis, the specific mediators on apoptotic and myeloid cells that facilitate efferocytosis and how these link to anabolic actions of PTH in bone. This proposal will delineate these pathways relative to osteoblast apoptosis and the support of new bone formation. This is a novel new coupling paradigm in bone - macrophages - efferyocytosing apoptotic osteoblasts - producing mesenchymal stem cell recruitment factors. Such a paradigm demonstrates a significant new step in the cell biologic processes in bone as well as robust potential for new avenues of therapeutic advantage for metabolic and inflammatory-mediated bone disease.
Parathyroid hormone (PTH) is currently used in humans to stimulate bone growth in patients with osteoporosis and shows potential for situations where wound healing in bone is needed;however, the mechanisms of how it works to build and facilitate healing in bone are not clear. PTH also stimulates cells in the bone marrow (i.e. specia types of blood cells) and the relationship between these cells and bone cells is unknown. This project will investigate the mechanisms of action of PTH relative to its ability to stimulate bone cell renewal through a cycle whereby dying cells provide signals to specialized blood cells which trigger them to recruit new bone forming cells. This information and innovation is critical in orde to elucidate the clinical potential of therapies to assist in bone healing.
| Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266 |
| Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176 |
| Michalski, Megan N; Seydel, Anna L; Siismets, Erica M et al. (2018) Inflammatory bone loss associated with MFG-E8 deficiency is rescued by teriparatide. FASEB J 32:3730-3741 |
| Michalski, Megan N; McCauley, Laurie K (2017) Macrophages and skeletal health. Pharmacol Ther 174:43-54 |
| Dang, Ming; Koh, Amy J; Jin, Xiaobing et al. (2017) Local pulsatile PTH delivery regenerates bone defects via enhanced bone remodeling in a cell-free scaffold. Biomaterials 114:1-9 |
| Koh, A J; Sinder, B P; Entezami, P et al. (2017) The skeletal impact of the chemotherapeutic agent etoposide. Osteoporos Int 28:2321-2333 |
| Sinder, Benjamin P; Zweifler, Laura; Koh, Amy J et al. (2017) Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis. J Bone Miner Res 32:2116-2127 |
| Wang, Chin-Wei Jeff; McCauley, Laurie K (2016) Osteoporosis and Periodontitis. Curr Osteoporos Rep 14:284-291 |
| Michalski, Megan N; Koh, Amy J; Weidner, Savannah et al. (2016) Modulation of Osteoblastic Cell Efferocytosis by Bone Marrow Macrophages. J Cell Biochem 117:2697-2706 |
| Wang, L; Tran, A B; Nociti Jr, F H et al. (2015) PTH and Vitamin D Repress DMP1 in Cementoblasts. J Dent Res 94:1408-16 |
Showing the most recent 10 out of 57 publications
